Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Enteritis Caused by Radiation
Interventions: SYN-020 Delayed Release Capsule; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Sunscreening Agent
Interventions: Coppertone (BAY987517); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Familial Mediterranean Fever
Interventions: colchicine sprinkle capsules; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glucose Intolerance, Gastric Bypass Surgery
Interventions: Ursodeoxycholic Acid, Placebos; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: TAK-385 T2 Formulation, TAK-385 T4 Formulation B, TAK-385 T4 Formulation C; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Aging
Interventions: NT-020, Placebo; Drug · Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 65 Years to 85 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Myelofibrosis
Interventions: Selinexor, Physician's Choice Treatment; Drug · Other
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Pasadena, California • Aurora, Colorado • Niles, Illinois + 1 more

Conditions: Achondroplasia
Interventions: Recifercept; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Aliso Viejo, California • Irvine, California • Long Beach, California + 3 more

Conditions: Duchenne Muscular Dystrophy
Interventions: HT-100; Drug
Lead sponsor: Akashi Therapeutics; Industry
Eligibility: 6 Years to 20 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Infections, Bacterial
Interventions: GSK2140944 (Single dose), GSK2140944 (Multiple dose); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pediatric Cancer, Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Soft Tissue Sarcomas, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumors
Interventions: Magnetic resonance high intensity focused ultrasound, Lyso-thermosensitive liposomal doxorubicin; Device · Drug
Lead sponsor: AeRang Kim; Other
Eligibility: Up to 30 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Volunteers
Interventions: Ritlecitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Sunscreening Agents
Interventions: BAY 987517; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Union, New Jersey

Conditions: Cystic Fibrosis
Interventions: VX-118; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Multiple Sclerosis
Interventions: gold nanocrystals; Drug
Lead sponsor: Clene Nanomedicine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Urinary Incontinence, Urinary Bladder, Overactive
Interventions: BOTOX®; Biological
Lead sponsor: Allergan; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 8
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more

Conditions: Healthy
Interventions: 25 mg Proellex, 50 mg Proellex; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteer
Interventions: Lebrikizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 4
States / cities: Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more

Conditions: Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions: Varespladib Methyl, Placebo, Standard of care (SOC); Drug
Lead sponsor: Ophirex, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more

Conditions: Healthy Volunteers
Interventions: Mitapivat tablet; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Cypress, California • Daytona Beach, Florida • Miami, Florida + 2 more

Conditions: Healthy
Interventions: Buprenorphine HCl/Naloxone HCl; Drug
Lead sponsor: NanoSHIFT LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
Interventions: TLC-ART; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Blood Pressure
Interventions: MENT or placebo; Drug
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020

18613 - Sun Protection Factor Assay

Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients

Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

Nutraceutical Effects on Long-Term Memory

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

18611 - Sun Protection Factor Assay

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.

OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)

Proellex Pharmacokinetics Bridging Study

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

First in Human Study of TLC-ART 101 (ACTU 2001)

A Two-part Trial Assessing the Effects of 7α-methyl-19-nortestosterone (MENT) on Blood Pressure in Normal Men: an Open-label Pilot Study Followed by a Randomized, Double-blind, Placebo-controlled Study